Lv11
40 积分 2024-08-02 加入
Efficacy and Safety of IGF‑1 Receptor Inhibitors for Thyroid Eye Disease: Systematic Review and Meta‑analysis of Randomized Controlled Trials
17天前
已完结
Efficacy and Safety of IGF-1 Receptor Inhibitors for Thyroid Eye Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials
17天前
已完结
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
3个月前
已完结
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
3个月前
已完结
BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non–Small Cell Lung Cancer
4个月前
已完结
Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer
4个月前
已关闭
Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer
4个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
4个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
